This trial looks at whether giving the drug pioglitazone to men with prostate cancer who are also on ADT will help improve insulin resistance.
- Insulin Resistance
- Prostate Cancer
1 Primary · 2 Secondary · Reporting Duration: 6 months
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
44 Total Participants · 2 Treatment Groups
Primary Treatment: Pioglitazone 30 mg · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 85 · Male Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment open for this particular research effort?
"According to the information on clinicaltrials.gov, this research is searching for participants and has been available since December 1st 2021 with edits having taken place as recently as June 30th 2022." - Anonymous Online Contributor
What is the usual purpose of administering Pioglitazone 30 mg?
"Pioglitazone 30 mg is typically prescribed to treat diabetes, yet it can also assist patients in tackling diabetic neuralgia and promoting a healthy lifestyle with diet and exercise." - Anonymous Online Contributor
Is the age cut-off for participation in this research trial below 30 years of age?
"Those hoping to be included in this clinical trial must fall within the age range of 18-85. The study features 101 studies for minors and 1422 research opportunities for seniors." - Anonymous Online Contributor
Is it possible for me to become a participant in this clinical trial?
"To qualify for this clinical trial, potential participants must exhibit insulin resistance and be between 18 to 85 years old. The total number of admitted patients is 44 individuals." - Anonymous Online Contributor
How many participants are enrolled in this research endeavor?
"Affirmative. According to the information on clinicaltrials.gov, this medical research was established on December 1st 2021 and is presently seeking 44 participants from a single site. The trial has been recently updated as of June 30th 2022." - Anonymous Online Contributor
Does the administration of Pioglitazone 30 mg pose any substantial health risks?
"Our group at Power analyzed the safety of Pioglitazone 30 mg and determined that this Phase 2 trial, which has some evidence supporting its security but no proof for efficacy, deserves a rating of 2." - Anonymous Online Contributor
Could you provide a catalog of research projects utilizing Pioglitazone 30 mg?
"Presently, there are 31 clinical trials examining the efficacy of Pioglitazone 30 mg. Of those, 4 have reached Phase 3 status. These studies primarily occur in Lausanne, Vaud; however 69 other locations worldwide are running these same trials." - Anonymous Online Contributor